ResearcherShanghai Jiao Tong UniversityNo recent work listed
Shilei Liu
Matched on ORCID iD 0000-0003-1700-4385; OpenAlex author ID A5100690916. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 3
- Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. Co-author DOI 10.7150/ijms.68404↗
- DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. Co-author DOI 10.7150/ijbs.55636↗
- Estrogen-Related Receptor-α Promotes Pancreatic Cancer Progression by Enhancing the Transcription of PAI1 and Activating the MEK/ERK Signaling Pathway Co-author DOI 10.21203/rs.3.rs-33052/v1↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wei Gong · 3 shared papers, 2020–2022 · strength 0.40
- Paper Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. DOI 10.7150/ijms.68404↗
- Paper DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pat… DOI 10.7150/ijbs.55636↗
- Paper Estrogen-Related Receptor-α Promotes Pancreatic Cancer Progression by Enhancing the Transcription of PAI1 and Activatin… DOI 10.21203/rs.3.rs-33052/v1↗
- Lei Zheng · 1 shared paper, 2022 · strength 0.15
- Ziyi Yang · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.